Cargando…
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in...
Autores principales: | Ludwig, Heinz, Beksac, Meral, Bladé, Joan, Boccadoro, Mario, Cavenagh, Jamie, Cavo, Michele, Dimopoulos, Meletios, Drach, Johannes, Einsele, Hermann, Facon, Thierry, Goldschmidt, Hartmut, Harousseau, Jean-Luc, Hess, Urs, Ketterer, Nicolas, Kropff, Martin, Mendeleeva, Larisa, Morgan, Gareth, Palumbo, Antonio, Plesner, Torben, San Miguel, Jesús, Shpilberg, Ofer, Sondergeld, Pia, Sonneveld, Pieter, Zweegman, Sonja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227886/ https://www.ncbi.nlm.nih.gov/pubmed/20086168 http://dx.doi.org/10.1634/theoncologist.2009-0203 |
Ejemplares similares
-
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010) -
Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
por: Moxley, Katherine M., et al.
Publicado: (2010) -
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
por: Aapro, Matti, et al.
Publicado: (2010) -
Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
por: Larkin, James M.G., et al.
Publicado: (2010) -
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010)